KRAS and neoplasm: Next generation sequencing (NGS) reveals a genetically diverse landscape (averaging >60 mutations/tumor) including four high frequency drivers (KRAS, CDKN2A, TP53, and SMAD4) and many additional heterogeneous genetic alterations.